Development and external validation of a 90-day mortality prediction model for comatose sepsis patients: impact of cerebrovascular disease and dementia

• by Yaoxi Tan, Yadong Shen, Yanting Zhang

• July 2, 2026

Nasal Continuous Positive Airway Pressure vs Nasal Intermittent Positive Pressure Ventilation in Preterm

• by Hui Zhang, Yijia Zhang, Lin Zeng, Xiaomei Tong, Meihua Piao, Haiying He, Changliang Zhao, Hua Xie, Zhi Zheng, Qiliang Cui, Yiyu Lai, Huiping Wang, Li Wang, Hongyan Liu, Xiuying Tian, Hui Wu, Lan Kang, Tongyan Han

• June 30, 2026

JAK inhibitors in rheumatoid arthritis-associated interstitial lung disease: a review of mechanisms and clinical evidence

• by Zhiying Wu, Li Jiang, Xu Zheng, Wanlin Zhou, Zuofeng Wang, Weilin Xie

• July 1, 2026

ASCO26: Julia Rotow, MD, Silevertinib in Lung Cancer

Dana-Farber Cancer Institute's Dr. Julia Rotow reported on a study looking at silevertinib, with data showing it may offer a new first-line option for hard-to-treat EGFR non-small cell lung cancer variants, with encouraging brain activity and manageable side effects.

• July 1, 2026

• 1 min